5-Amino-1MQ Capsules: What the Research Actually Shows

5-Amino-1MQ capsules are an oral, research-only form of 5-amino-1-methylquinolinium, a small-molecule NNMT inhibitor studied for its effects on fat metabolism and energy balance. They are not FDA-approved for human use, and no human clinical trial has established a safe or effective dose. Nearly everything known about the compound comes from cell cultures and rodent studies.

What Is 5-Amino-1MQ?

5-Amino-1MQ blocks nicotinamide N-methyltransferase (NNMT), an enzyme that consumes SAM (S-adenosylmethionine) and helps regulate NAD+ and methyl-group balance in cells. Fat tissue with high NNMT activity tends to store more fat and release less of it.

When NNMT is inhibited in laboratory models, adipocytes release more stored fat and burn more energy. Researchers also report shifts in glucose tolerance and body weight in diet-induced obese mice.

The capsule format is simply a delivery method. The phrase "5-amino-1mq capsules 50mg" is one of the most common ways people search, because many vendors standardize on 50 mg of powder per capsule, with 100 mg versions also available.

Naming is inconsistent across suppliers. You may see the compound listed as 5-amino-1MQ, 5-amino-1-methylquinolinium, or an internal catalog code, so checking the chemical identity matters more than the label wording.

5-Amino-1MQ Benefits Reported in Research

Findings on this compound are early and largely limited to animals. Reported observations include:

• Lower body weight and fat mass in diet-induced obese mice
• Increased lipolysis in isolated fat cells
• Improved glucose tolerance and insulin sensitivity markers
• Rising cellular NAD+ as NNMT activity falls

None of these outcomes have been confirmed in controlled human trials. Media coverage often describes 5-amino-1mq benefits in language that sounds more definitive than the underlying data, which comes from short-term rodent work rather than clinical studies.

5-Amino-1MQ Dosage: What the Literature Says

There is no established human dose. Any specific protocol you see online is extrapolated from animal work or repeated from vendor suggestions, not from clinical evidence.

Setting	Reported dose	Route	Notes
Mice (diet-induced obesity)	Low mg/kg per day (often cited near 5 mg/kg)	Oral gavage	Short-term reductions in fat mass and body weight reported
Cell culture	Micromolar concentrations	In vitro	Direct NNMT inhibition and lipolysis measured
Vendor label guidance	Commonly 50–150 mg per day	Oral capsule	Not validated in humans; no safety data
Humans	None established	—	No published clinical trials

Animal doses do not translate directly to people, so 5-amino-1mq dosage discussions should always state which model is being referenced. Body-surface-area scaling is a common estimate, but it remains an estimate rather than a recommendation.

5-Amino-1MQ Capsules vs Injection

Injectables dominate the research literature, while capsules dominate the consumer market. The two formats differ in more than convenience.

Factor	Oral capsules	Injectable (subQ/IM)
Bioavailability	Uncertain; possible poor absorption and first-pass metabolism	Direct delivery into circulation
Purity verification	Difficult; capsule fill is hard to confirm	Requires sterile technique and lab-grade sourcing
Handling risk	Low; no needles	Infection, contamination, injection-site reactions
Research precedent	Minimal	Most published in vivo studies
Cost and storage	Lower cost, simple storage	Higher cost, cold chain, sharps disposal

Most published mouse work used oral gavage rather than capsules, so "5-amino-1mq capsules vs injection" is partly a question about formulation quality and honest labeling as much as it is about pharmacology.

How It Compares With SLU-PP-332 and MOTS-c

These three compounds appear together in metabolic research discussions, but they act through completely different mechanisms. SLU-PP-332 activates estrogen-related receptors (ERRs) and behaves like an exercise mimetic in mice, while MOTS-c is a mitochondrial-derived peptide tied to metabolic homeostasis.

Compound	Mechanism	Typical research route	Human data
5-Amino-1MQ	NNMT inhibitor	Oral gavage; in vitro	None
SLU-PP-332	ERR agonist	Injection in rodent studies	None
MOTS-c	Mitochondrial-derived peptide	Injection in rodent studies	Early pilot data on metabolic markers

Because the targets differ, combining them is not a case of stacking more of the same effect. A "slu-pp-332 vs 5-amino-1mq" comparison is really a comparison of two separate research questions. The same is true of a "mots-c vs 5-amino-1mq" analysis.

Safety and Legal Status

5-Amino-1MQ is sold as a research chemical, usually labeled "not for human consumption." It is not FDA-approved as a drug, and it is not a legal dietary supplement ingredient in the United States.

NNMT sits inside the body's methylation network, so blocking it for long periods could affect pathways far beyond fat metabolism. Laboratory studies were short, used controlled doses, and monitored animals closely — conditions that do not exist with unregulated self-dosing.

Anyone weighing a research compound should speak with a healthcare professional first and stay skeptical of vendors promising outcomes no study has demonstrated.

Bottom Line

5-Amino-1MQ capsules deliver a compound that has shown promising metabolic results in mice and cells but has never been tested in humans for efficacy or safety. Capsules are convenient but poorly studied, while injection has more research precedent and more handling risk. No human trial has validated any dose, benefit, or long-term effect of this compound.

COMMON QUESTIONS

Frequently Asked Questions

Are 5-amino-1MQ capsules safe to take?

There is no human safety data for 5-amino-1MQ. The compound is sold as a research chemical labeled not for human consumption, and it is not FDA-approved for any use. Because it inhibits an enzyme involved in the body's methylation pathways, long-term effects in people are unknown.

What is the recommended 5-amino-1MQ dosage?

No human dose has been established. Published mouse studies used low milligram-per-kilogram oral doses, often cited near 5 mg/kg per day, and vendor labels frequently suggest 50–150 mg daily without supporting clinical data. Animal doses do not convert directly into safe human doses.

Do 5-amino-1MQ capsules work as well as injections?

There is no head-to-head human study comparing the two formats. Oral bioavailability of 5-amino-1MQ is uncertain because the compound may be poorly absorbed or broken down before reaching circulation, and most published animal work used oral gavage or injection rather than capsules.